Eidos Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present a company overview at the 37th Annual J.P. Morgan...
Eidos Therapeutics Appoints William Lis to Board of Directors
December 06, 2018 16:15 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in...
Eidos Therapeutics to Present at Two Upcoming Investor Conferences
November 14, 2018 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present a company overview at two upcoming investor conferences. ...
Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy
November 10, 2018 10:00 ET
|
Eidos Therapeutics, Inc.
AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days AG10 Resulted in Average TTR Stabilization Greater than 90% in All Actively Treated Subjects at Day 28 AG10...
Eidos Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 06, 2018 16:05 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in...
Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results
October 29, 2018 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will host a conference call and webcast to discuss the results of its...
Eidos Therapeutics Receives Positive Opinion for Orphan Designation from the European Medicines Agency for AG10, a Potent Oral Stabilizer for the Treatment of Transthyretin Amyloidosis
October 26, 2018 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), announced today that the Committee for Orphan Medicinal Products (COMP) within the European Medicines...
Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation
October 05, 2018 09:10 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced that results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic...
FDA Grants Orphan Drug Designation to Eidos Therapeutics’ Product Candidate, AG10, for Treatment of Transthyretin Amyloidosis
October 03, 2018 14:35 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in...
Eidos Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
September 25, 2018 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will participate in a fireside chat at the Leerink Partners...